Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in subjects with the stable dose of Methadone and on the PK of Buprenorphine in subjects with the stable dose of Buprenorphine.
IND number: 101,943
Primary purpose: Other: Phase 1 Clinical Pharmacology drug interaction study in healthy subjects
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1: Methadone + DCV 3DAA FDC + BMS-791325 | Experimental | Methadone 40-120 mg tablet or solution orally once on Day 1 Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12 |
|
| Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325 | Active Comparator | Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1 Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methadone | Drug |
| ||
| DCV 3DAA FDC |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum observed concentration (Cmax) of R-Methadone for Part 1 | 24 timepoints up to Day 13 | |
| Area under the concentration-time curve in one dosing interval (AUC(TAU)) of R-Methadone for Part 1 | 24 timepoints up to Day 13 | |
| Cmax of Buprenorphine and Norbuprenorphine for Part 2 | 24 timepoints up to Day 13 | |
| AUC(TAU) of Buprenorphine and Norbuprenorphine for Part 2 | 24 timepoints up to Day 13 |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax of S-Methadone and Total Methadone for Part 1 | 24 timepoints up to 13 days | |
| AUC(TAU) of S-Methadone and Total Methadone for Part 1 | 24 timepoints up to 13 days | |
Not provided
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anaheim Clinical Trials Llc | Anaheim | California | 92801 | United States | ||
| Cri Lifetree |
Not provided
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
Not provided
Not provided
| ID | Term |
|---|---|
| D008691 | Methadone |
| C587012 | 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide |
| D002047 | Buprenorphine |
| D009270 | Naloxone |
| ID | Term |
|---|---|
| D007659 | Ketones |
| D009930 | Organic Chemicals |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| BMS-791325 | Drug |
|
| Buprenorphine | Drug |
|
| Naloxone | Drug |
|
| Concentration at 24 hours (C24) of S-Methadone, Total Methadone and R-Methadone for Part 1 |
| 24 timepoints up to 13 days |
| Time of maximum observed concentration (Tmax) of S-Methadone, Total Methadone and R-Methadone for Part 1 | 24 timepoints up to 13 days |
| C24 of Buprenorphine and Norbuprenorphine for Part 2 | 24 timepoints up to 13 days |
| Tmax of Buprenorphine and Norbuprenorphine for Part 2 | 24 timepoints up to 13 days |
| Ratio of metabolite AUC(TAU) to parent AUC(TAU) (MR_AUC(TAU)) of Norbuprenorphine to Buprenorphine | 24 timepoints up to 13 days |
| Cmax of of Daclatasvir (DCV) , Asunaprevir (ASV) , BMS-791325, and BMS-794712 | 10 timepoints on Day 12 |
| AUC(TAU) of DCV, ASV, BMS-791325, and BMS-794712 | 10 timepoints on Day 12 |
| Concentration at 12 hours (C12) of DCV, ASV, BMS-791325, and BMS-794712 | 10 timepoints on Day 12 |
| Tmax of DCV, ASV, BMS-791325, and BMS-794712 | 10 timepoints on Day 12 |
| MR_AUC(TAU) for BMS-794712 to BMS-791325 | 10 timepoints on Day 12 |
| Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), death and AEs leading to discontinuation | Up to day 13 |
| Results of vital signs, Electrocardiograms (ECGs), Physical Examinations (PEs) and clinical labs | Up to day 13 |
| Scores of Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), Objective Opiate Withdrawal Scale (OOWS), and Opiate Overdose Assessment (OOA) | Up to day 13 |
| Philadelphia |
| Pennsylvania |
| 19139 |
| United States |
| Lifetree Clinical Research | Salt Lake City | Utah | 84106 | United States |
| D014777 |
| Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D000470 |
| Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |